Smith+Nephew Announces a Marketing Collaboration with Movendo Technology

Smith+Nephew today announced a marketing collaboration with Movendo Technology (Genoa, Italy) that will add personalized robotic patient rehabilitation capability to Smith+Nephew’s Real Intelligence enabling technology solutions, creating a fully digitized patient pathway from the pre-op stage to post-rehab phase.

The collaboration has launched in Europe and will expand to other regions in the near future.

Movendo Technology’s multifunctional rehabilitation device, HUNOVA, is able to analyze 130 different biomechanics parameters of the lower limb before and after surgery, generating a bespoke functional evaluation knee index. This provides a personalized patient recovery program to support the return of strength and function of the joint’s articulation. The index can also be extended to the hip and ankle.

Smith+Nephew’s Real Intelligence ecosystem addresses clinical challenges through the continuum of care including patient engagement, pre-operative planning, digital and robotic surgery, post-operative assessment, and outcomes measurement. Smith+Nephew’s next-generation robotics-assisted platform, the CORI Surgical System, is scheduled to launch in Europe during the first half of 2021 after a successful introduction in the US last year.

“We are thrilled that this collaboration will start in Europe,” said Peter Coenen, President EMEA, Smith+Nephew. “By combining our innovations in robotics-assisted surgical systems with HUNOVA Robotic technology, we bring together personalized implant placement and soft tissue balancing with a rehabilitation treatment to deliver greater benefits to patients, accelerate recovery and improve function.”

“We are extremely proud and excited about this new partnership that will make robotics-assisted surgery and rehabilitation an integrated, more effective, and engaging process,” said Simone Ungaro, CEO of Movendo. “I am looking forward to bringing this innovative concept world-wide in collaboration with Smith+Nephew.”

The collaboration further emphasizes Smith+Nephew’s commitment to data-driven enabling technologies that allow our customers to provide the highest level of care to their patients.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”